{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T14:19:21Z","timestamp":1788963561372,"version":"build-2803163510"},"reference-count":51,"publisher":"MDPI AG","issue":"18","license":[{"start":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T00:00:00Z","timestamp":1788912000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int. J. Mol. Sci.","IJMS"],"abstract":"<jats:p>Autoimmune diseases encompass nearly 100 distinct conditions characterized by dysregulated immune responses against self-antigens, resulting in tissue damage, chronic inflammation, and substantial morbidity. Over recent decades, the global burden of autoimmune diseases has increased, while their therapeutic management has undergone a paradigm shift from broad, nonspecific immunosuppression toward targeted biologic therapies. Among these, antibody-based therapeutics, including monoclonal antibodies targeting cytokines, cell-surface molecules, and co-stimulatory pathways, have transformed the treatment of numerous systemic and organ-specific autoimmune disorders. Nevertheless, important challenges remain, including primary non-response, secondary loss of efficacy related to immunogenicity or disease adaptation, increased susceptibility to infections, and mechanistic redundancy among therapeutic targets. This review provides a comprehensive overview of the cellular and molecular mechanisms underlying antibody-based therapies, summarizes major therapeutic target classes across autoimmune diseases, and examines their clinical and mechanistic limitations. Emerging therapeutic platforms, including bispecific antibodies, antibody\u2013drug conjugates (ADCs), novel Fc-engineering, and cellular approaches such as CD19-targeted chimeric antigen receptor (CAR)-T therapy, are also discussed. Finally, antigen-specific immunotherapies designed to restore antigen-specific immune tolerance while preserving systemic host defense are explored. These approaches may represent an important next frontier in the treatment of autoimmune diseases, moving beyond broad systemic immune modulation toward more selective and durable immune control.<\/jats:p>","DOI":"10.3390\/ijms27188030","type":"journal-article","created":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T14:02:48Z","timestamp":1788962568000},"page":"8030","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Antibody-Based Therapeutics in Autoimmune Diseases: Mechanisms, Challenges, and Future Perspectives"],"prefix":"10.3390","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7919-1326","authenticated-orcid":false,"given":"Naim","family":"Mahroum","sequence":"first","affiliation":[{"name":"International School of Medicine, Istanbul Medipol University, Kavac\u0131k, G\u00f6ztepe Mah, Atat\u00fcrk Cd. No: 40, Beykoz, 34810 Istanbul, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,9,9]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"102945","DOI":"10.1016\/j.autrev.2021.102945","article-title":"The mosaic of autoimmunity\u2014A taste for more. The 12th international congress of autoimmunity 2021 (AUTO12) virtual","volume":"20","author":"Mahroum","year":"2021","journal-title":"Autoimmun. Rev."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"e70262","DOI":"10.1002\/mco2.70262","article-title":"Autoimmune Diseases: Molecular Pathogenesis and Therapeutic Targets","volume":"6","author":"Song","year":"2025","journal-title":"MedComm"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1007\/s40262-024-01419-7","article-title":"Pharmacokinetics and Pharmacodynamics of Systemic Corticosteroids in Autoimmune and Inflammatory Diseases: A Review of Current Evidence","volume":"63","author":"Mohlmann","year":"2024","journal-title":"Clin. Pharmacokinet."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Balogh, L., Olah, K., Santa, S., Majerhoffer, N., and Nemeth, T. (2024). Novel and potential future therapeutic options in systemic autoimmune diseases. Front. Immunol., 15.","DOI":"10.3389\/fimmu.2024.1249500"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1038\/s41573-024-01053-9","article-title":"Targeting the TNF and TNFR superfamilies in autoimmune disease and cancer","volume":"23","author":"Croft","year":"2024","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Pizano-Martinez, O., Mendieta-Condado, E., Vazquez-Del Mercado, M., Martinez-Garcia, E.A., Chavarria-Avila, E., Ortuno-Sahagun, D., and Marquez-Aguirre, A.L. (2023). Anti-Drug Antibodies in the Biological Therapy of Autoimmune Rheumatic Diseases. J. Clin. Med., 12.","DOI":"10.3390\/jcm12093271"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1097\/BOR.0000000000000995","article-title":"Long-term safety of biologic and targeted synthetic disease modifying drugs in rheumatology","volume":"36","author":"Barth","year":"2024","journal-title":"Curr. Opin. Rheumatol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1038\/ncprheum0895","article-title":"Nature and functions of autoantibodies","volume":"4","author":"Elkon","year":"2008","journal-title":"Nat. Clin. Pract. Rheumatol."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Qi, J., Liu, C., Bai, Z., Li, X., and Yao, G. (2023). T follicular helper cells and T follicular regulatory cells in autoimmune diseases. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1178792"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1038\/nrrheum.2013.30","article-title":"Protective autoantibodies in the rheumatic diseases: Lessons for therapy","volume":"9","author":"Silverman","year":"2013","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1038\/s41584-026-01365-7","article-title":"Germinal-centre and extrafollicular B cell pathways in systemic lupus erythematosus","volume":"22","author":"Zhu","year":"2026","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1038\/s41584-019-0211-0","article-title":"B cell checkpoints in autoimmune rheumatic diseases","volume":"15","author":"Rubin","year":"2019","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1111\/joim.12163","article-title":"Pathogenic immune mechanisms at the neuromuscular synapse: The role of specific antibody-binding epitopes in myasthenia gravis","volume":"275","author":"Huijbers","year":"2014","journal-title":"J. Intern. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1016\/j.cell.2010.02.043","article-title":"Anti-inflammatory Agents: Present and Future","volume":"140","author":"Dinarello","year":"2010","journal-title":"Cell"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1093\/intimm\/dxu102","article-title":"Anti-TNF therapy: Past, present and future","volume":"27","author":"Monaco","year":"2015","journal-title":"Int. Immunol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/s41584-020-0419-z","article-title":"Translating IL-6 biology into effective treatments","volume":"16","author":"Choy","year":"2020","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2534","DOI":"10.1056\/NEJMoa1505066","article-title":"Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis","volume":"373","author":"Baeten","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1146\/annurev-immunol-083122-044829","article-title":"B Cell-Directed Therapy in Autoimmunity","volume":"42","author":"Abeles","year":"2024","journal-title":"Annu. Rev. Immunol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1136\/ard-2024-225727","article-title":"B-cell depletion in autoimmune diseases","volume":"83","author":"Schett","year":"2024","journal-title":"Ann. Rheum. Dis."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"104002","DOI":"10.1016\/j.autrev.2026.104002","article-title":"Autoimmunity in the era of immune checkpoint inhibitors: The evolving epidemiology of autoimmune diseases and the possible impact of COVID-19","volume":"25","author":"Mahroum","year":"2026","journal-title":"Autoimmun. Rev."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"kyad029","DOI":"10.1093\/discim\/kyad029","article-title":"The effect of abatacept on T-cell activation is not long-lived in vivo","volume":"3","author":"Scales","year":"2024","journal-title":"Discov. Immunol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1056\/NEJMe020157","article-title":"Alpha4 integrins as therapeutic targets in autoimmune disease","volume":"348","author":"Engelhardt","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1215734","article-title":"Vedolizumab as induction and maintenance therapy for ulcerative colitis","volume":"369","author":"Feagan","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Wang, W., Erbe, A.K., Hank, J.A., Morris, Z.S., and Sondel, P.M. (2015). NK Cell-Mediated Antibody-Dependent Cellular Cytotoxicity in Cancer Immunotherapy. Front. Immunol., 6.","DOI":"10.3389\/fimmu.2015.00368"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/S0065-2776(07)96005-8","article-title":"Fc-receptors as regulators of immunity","volume":"96","author":"Nimmerjahn","year":"2007","journal-title":"Adv. Immunol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1007\/s40259-022-00559-1","article-title":"Assessing Immunogenicity of Biologic Drugs in Inflammatory Joint Diseases: Progress Towards Personalized Medicine","volume":"36","author":"Gehin","year":"2022","journal-title":"BioDrugs"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s40259-017-0231-8","article-title":"Immunogenicity of Biologics in Chronic Inflammatory Diseases: A Systematic Review","volume":"31","author":"Strand","year":"2017","journal-title":"BioDrugs"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1136\/annrheumdis-2012-202545","article-title":"Antidrug antibodies (ADAb) to tumour necrosis factor (TNF)-specific neutralising agents in chronic inflammatory diseases: A real issue, a clinical perspective","volume":"72","author":"Vincent","year":"2013","journal-title":"Ann. Rheum. Dis."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1136\/ard-2022-223335","article-title":"2022 EULAR recommendations for screening and prophylaxis of chronic and opportunistic infections in adults with autoimmune inflammatory rheumatic diseases","volume":"82","author":"Fragoulis","year":"2023","journal-title":"Ann. Rheum. Dis."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/ard-2022-223356","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update","volume":"82","author":"Smolen","year":"2023","journal-title":"Ann. Rheum. Dis."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2364","DOI":"10.1016\/j.jid.2024.05.015","article-title":"Paradoxical Psoriasis: An Updated Review of Clinical Features, Pathogenesis, and Treatment Options","volume":"144","author":"Maronese","year":"2024","journal-title":"J. Investig. Dermatol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"e002898","DOI":"10.1136\/rmdopen-2022-002898","article-title":"Points to consider for cost-effective use of biological and targeted synthetic DMARDs in inflammatory rheumatic diseases: Results from an umbrella review and international Delphi study","volume":"9","author":"Aletaha","year":"2023","journal-title":"RMD Open"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"101812","DOI":"10.1016\/j.berh.2022.101812","article-title":"Personalized medicine in rheumatoid arthritis: Combining biomarkers and patient preferences to guide therapeutic decisions","volume":"36","author":"Thomas","year":"2022","journal-title":"Best. Pract. Res. Clin. Rheumatol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"105578","DOI":"10.1016\/j.jbspin.2023.105578","article-title":"Rationale, current state and opportunities in combining biologic disease modifying antirheumatic drugs in rheumatoid and psoriatic arthritis","volume":"90","author":"Mutlu","year":"2023","journal-title":"Jt. Bone Spine"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"e2149675","DOI":"10.1002\/eji.202149675","article-title":"Targeting B cells and plasma cells in autoimmune diseases: From established treatments to novel therapeutic approaches","volume":"53","author":"Frazzei","year":"2023","journal-title":"Eur. J. Immunol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1080\/17425247.2023.2292697","article-title":"Targeted transport of biotherapeutics at the blood-brain barrier","volume":"20","author":"Moos","year":"2023","journal-title":"Expert. Opin. Drug Deliv."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/s41573-019-0028-1","article-title":"Bispecific antibodies: A mechanistic review of the pipeline","volume":"18","author":"Labrijn","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"e003855","DOI":"10.1136\/rmdopen-2023-003855","article-title":"Bimekizumab treatment in patients with active psoriatic arthritis and prior inadequate response to tumour necrosis factor inhibitors: 52-week safety and efficacy from the phase III BE COMPLETE study and its open-label extension BE VITAL","volume":"10","author":"Coates","year":"2024","journal-title":"RMD Open"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0140-6736(22)02302-9","article-title":"Bimekizumab in patients with psoriatic arthritis, naive to biologic treatment: A randomised, double-blind, placebo-controlled, phase 3 trial (BE OPTIMAL)","volume":"401","author":"McInnes","year":"2023","journal-title":"Lancet"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1136\/ard-2022-223595","article-title":"Efficacy and safety of bimekizumab in axial spondyloarthritis: Results of two parallel phase 3 randomised controlled trials","volume":"82","author":"Deodhar","year":"2023","journal-title":"Ann. Rheum. Dis."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"4496","DOI":"10.1021\/acs.jmedchem.2c00339","article-title":"Antibody-Drug Conjugates for Immunology","volume":"65","author":"Dragovich","year":"2022","journal-title":"J. Med. Chem."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"2348","DOI":"10.1039\/D3MD00336A","article-title":"ValCitGlyPro-dexamethasone antibody conjugates selectively suppress the activation of human monocytes","volume":"14","author":"Howe","year":"2023","journal-title":"RSC Med. Chem."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1038\/mt.2016.175","article-title":"Targeted Delivery of an Anti-inflammatory PDE4 Inhibitor to Immune Cells via an Antibody-drug Conjugate","volume":"24","author":"Yu","year":"2016","journal-title":"Mol. Ther."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1186\/s13075-024-03452-0","article-title":"Therapeutic potential of antibody-drug conjugates possessing bifunctional anti-inflammatory action in the pathogenies of rheumatoid arthritis","volume":"26","author":"Dixit","year":"2024","journal-title":"Arthritis Res. Ther."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/S1474-4422(21)00159-9","article-title":"Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): A multicentre, randomised, placebo-controlled, phase 3 trial","volume":"20","author":"Howard","year":"2021","journal-title":"Lancet Neurol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1038\/s41584-024-01201-w","article-title":"Antigen-specific immunotherapies for autoimmune disease","volume":"21","author":"Buckner","year":"2025","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"101940","DOI":"10.1016\/j.berh.2024.101940","article-title":"Dendritic cells and antigen-specific immunotherapy in autoimmune rheumatic diseases","volume":"38","author":"Cai","year":"2024","journal-title":"Best. Pract. Res. Clin. Rheumatol."},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Cheever, A., Kang, C.C., O\u2019Neill, K.L., and Weber, K.S. (2024). Application of novel CAR technologies to improve treatment of autoimmune disease. Front. Immunol., 15.","DOI":"10.3389\/fimmu.2024.1465191"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1038\/s41591-022-02017-5","article-title":"Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus","volume":"28","author":"Mackensen","year":"2022","journal-title":"Nat. Med."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1056\/NEJMoa2308917","article-title":"CD19 CAR T-Cell Therapy in Autoimmune Disease\u2014A Case Series with Follow-up","volume":"390","author":"Muller","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Biswas, B., Munquad, S., Roy Choudhury, K., Cherayil, B.J., and Chaudhuri, A. (2026). Applications of artificial intelligence in systemic lupus erythematosus: Integrating multi-omics data for precision medicine. Front. Immunol., 17.","DOI":"10.3389\/fimmu.2026.1804598"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/18\/8030\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T14:04:25Z","timestamp":1788962665000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/18\/8030"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,9]]},"references-count":51,"journal-issue":{"issue":"18","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["ijms27188030"],"URL":"https:\/\/doi.org\/10.3390\/ijms27188030","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,9]]}}}